Diagnosing Alzheimer’s disease accurately and promptly is crucial for effective management and care. This condition, characterized by progressive memory loss and cognitive decline, requires a multifaceted approach to diagnosis and a comprehensive treatment strategy. This guide provides an in-depth look at the latest methods for Alzheimer’s diagnosis and the range of treatments available in 2024.
Understanding Alzheimer’s Diagnosis
Explaining your symptoms is a critical first step in diagnosing Alzheimer’s. Input from family or close friends can be invaluable in understanding the symptoms and their impact on daily life. Doctors use various tests to diagnose Alzheimer’s disease, starting with assessing memory and thinking skills.
Blood tests and brain imaging are also essential to rule out other conditions that might be causing similar symptoms. These tests can also identify specific proteins in the brain associated with Alzheimer’s. This comprehensive evaluation allows healthcare professionals to pinpoint the cause of dementia symptoms more accurately.
Historically, a definitive Alzheimer’s diagnosis was only possible post-mortem through microscopic examination of brain tissue for plaques and tangles. However, advancements in medical science now enable healthcare professionals and researchers to diagnose Alzheimer’s with greater certainty during a person’s lifetime.
This improved diagnostic accuracy is largely due to the integration of biomarker tests with traditional methods. Biomarkers can detect the presence of plaques and tangles in the living brain. These tests include specialized Positron Emission Tomography (PET) scans. Furthermore, amyloid and tau proteins, key indicators of Alzheimer’s, can be measured in blood and cerebrospinal fluid (CSF). Recent breakthroughs in blood biomarker testing have shown remarkable accuracy in predicting the presence of amyloid in the brain.
While initially used mainly in research settings and clinical trials, biomarker tests are increasingly becoming part of standard clinical practice. Healthcare professionals now use them alongside other diagnostic tools to diagnose Alzheimer’s disease and determine the stage of the disease, whether early or later.
Diagnostic Tests for Alzheimer’s Disease
A comprehensive Alzheimer’s diagnosis typically involves several key tests:
Physical and Neurological Exam
A fundamental part of the diagnostic process is a thorough physical and neurological examination conducted by a healthcare professional. This exam assesses various aspects of neurological function, including:
- Reflexes: Testing reflexes helps evaluate nerve function.
- Muscle Tone and Strength: Assessing muscle tone and strength can identify motor impairments.
- Mobility Assessment: Evaluating the ability to stand from a chair and walk helps assess balance and coordination.
- Sensory Functions: Testing sight and hearing ensures that sensory deficits are not contributing to cognitive issues.
- Coordination: Assessing coordination skills helps identify neurological problems.
- Balance: Evaluating balance is crucial for identifying risks of falls and neurological disorders.
Lab Tests
Laboratory blood tests are crucial for excluding other potential causes of memory loss and confusion. These tests can detect conditions such as thyroid disorders or vitamin deficiencies, which can mimic dementia symptoms.
Emerging blood tests are now capable of measuring beta-amyloid and tau protein levels in the blood. While not universally available and potentially not covered by insurance, these tests represent a significant advancement in non-invasive Alzheimer’s diagnostics.
Mental Status and Neuropsychological Testing
Healthcare professionals use mental status tests to quickly evaluate memory and cognitive abilities. More detailed neuropsychological tests provide a comprehensive assessment of cognitive function compared to individuals of similar age and education. These tests are essential for establishing a baseline diagnosis and monitoring symptom progression over time.
Brain Imaging
Brain imaging techniques play a vital role in diagnosing Alzheimer’s and ruling out other conditions.
Brain Scan Images for Diagnosis of Alzheimer’s Disease
Brain scan images for diagnosis of Alzheimer’s disease: Fluorodeoxyglucose PET (FDG PET) scans visualize brain metabolism. The scans show a healthy brain (black and blue areas indicating healthy metabolism), a brain with mild cognitive impairment (MCI), and a brain with Alzheimer’s disease (green, yellow, and red areas showing worsening metabolism).
Brain imaging helps identify visible changes in the brain due to conditions other than Alzheimer’s, such as strokes, injuries, or tumors. Newer imaging techniques are specifically designed to detect Alzheimer’s-related brain changes, like amyloid plaques and neurofibrillary tangles. These advanced tests are primarily used in major medical centers and research trials.
Brain structure imaging includes:
- Magnetic Resonance Imaging (MRI): MRI uses radio waves and magnetic fields to create detailed brain images. It can reveal shrinkage in brain regions associated with Alzheimer’s and exclude other conditions. MRI is generally preferred over CT scans for dementia evaluation and is used before and during certain Alzheimer’s medications to monitor for side effects.
- Computerized Tomography (CT): CT scans use X-ray technology to produce cross-sectional brain images. CT scans are mainly used to rule out tumors, strokes, and head injuries.
PET scans are crucial for visualizing disease processes in the brain. These scans use a radioactive tracer to highlight specific brain features:
- Fluorodeoxyglucose (FDG) PET Imaging: FDG PET scans show brain areas with reduced glucose metabolism, indicating neuronal dysfunction. Patterns of reduced metabolism can help distinguish Alzheimer’s from other dementias.
- Amyloid PET Imaging: This technique measures amyloid plaques in the brain and is primarily used in research or in cases of unusual or early-onset dementia.
- Tau PET Imaging: Tau PET scans quantify neurofibrillary tangles, another hallmark of Alzheimer’s.
In some cases, particularly with rapid symptom progression or younger individuals, cerebrospinal fluid (CSF) analysis may be used to measure amyloid and tau levels.
The Future of Alzheimer’s Diagnostic Tests
Research emphasizes the growing role of biomarker tests in diagnosing Alzheimer’s. These tests, used alongside clinical assessments, can identify biological markers of the disease in the brain after symptoms appear. While biomarker tests can detect early signs of Alzheimer’s before symptoms manifest, they are not yet recommended for routine screening in asymptomatic individuals. The availability of biomarker tests can vary depending on location and healthcare facilities.
Genetic testing is generally not recommended for most individuals with suspected Alzheimer’s. However, it may be considered for those with a strong family history of early-onset Alzheimer’s. Genetic counseling is advised to discuss the potential risks and benefits of genetic testing before proceeding.
Alzheimer’s Treatment Strategies in 2024
Alzheimer’s treatments in 2024 include medications to manage symptoms and newer therapies aimed at slowing the progression of cognitive and functional decline. These newer disease-modifying treatments are approved for individuals in the early stages of Alzheimer’s.
Medications for Alzheimer’s Disease
Medications for Alzheimer’s can be broadly categorized into symptom-relieving drugs and disease-modifying agents.
Symptom Management Medications
Two primary types of medications are used to manage cognitive symptoms:
- Cholinesterase Inhibitors: These drugs enhance cell-to-cell communication by increasing the levels of acetylcholine, a neurotransmitter reduced in Alzheimer’s disease. Often the first medications prescribed, they provide modest symptom improvement. Cholinesterase inhibitors may also alleviate behavioral symptoms like agitation and depression. They are available in oral and transdermal patch forms. Common examples include donepezil (Aricept, Adlarity), galantamine, and rivastigmine (Exelon patch). Common side effects include gastrointestinal issues (diarrhea, nausea, appetite loss) and sleep disturbances. In individuals with certain heart conditions, irregular heartbeat is a potential serious side effect.
- Memantine (Namenda): Memantine works through a different brain cell communication pathway, slowing symptom progression in moderate to severe Alzheimer’s. It is sometimes used with cholinesterase inhibitors. Side effects are relatively infrequent but can include dizziness and confusion.
Disease-Modifying Medications
Recently, the FDA has approved medications designed to slow the underlying disease process of Alzheimer’s by targeting amyloid plaques:
- Lecanemab-irmb (Leqembi): Administered as an intravenous (IV) infusion every two weeks, lecanemab helps reduce amyloid plaques. Infusion-related reactions, such as fever, flu-like symptoms, nausea, vomiting, dizziness, heart rate changes, and breathing difficulties, are potential side effects.
- Donanemab-azbt (Kisunla): Given as an IV infusion every four weeks, donanemab also targets amyloid plaques. Side effects are similar to lecanemab, including flu-like symptoms, nausea, vomiting, headache, breathing problems, and blood pressure changes.
Both lecanemab and donanemab carry risks of brain swelling (ARIA-E) or microbleeds (ARIA-H), which can be serious. Regular MRI monitoring is recommended before and during treatment. Individuals with the APOE e4 gene variant have a higher risk of these side effects, and genetic testing is often recommended before starting treatment. Caution is advised for those on blood thinners due to increased bleeding risk. Ongoing research is further evaluating the benefits and risks of these newer medications, including their effectiveness for those at risk of Alzheimer’s.
Antidepressants and other medications may be prescribed to manage behavioral and psychological symptoms associated with Alzheimer’s.
Creating a Safe and Supportive Environment
Adapting the living environment to the needs of someone with Alzheimer’s is a critical aspect of care. Establishing routines and simplifying tasks can significantly enhance quality of life.
Strategies to support well-being and function include:
- Consistent Placement of Essentials: Keep keys, wallets, phones, and other important items in the same place to prevent loss.
- Medication Management: Securely store medications and use daily checklists to track doses.
- Automated Finances: Set up automatic bill payments and direct deposits.
- Location Tracking: Ensure the person carries a mobile phone with GPS tracking and pre-programmed important numbers.
- Home Safety Measures: Install door and window alarms.
- Routine Schedules: Maintain consistent daily routines and appointment schedules.
- Visual Aids: Use calendars and whiteboards to track schedules and tasks.
- Home Modifications: Remove unnecessary furniture, clutter, and throw rugs. Install handrails in bathrooms and stairways. Ensure comfortable, traction-providing footwear.
- Minimize Mirrors: Mirrors can be confusing or frightening for individuals with Alzheimer’s.
- Identification: Ensure the person carries ID or wears a medical alert bracelet.
- Familiar Objects: Keep meaningful photos and objects around the home to provide comfort and familiarity.
Clinical Trials for Alzheimer’s Disease
Participating in clinical trials offers access to cutting-edge treatments and contributes to advancing Alzheimer’s research. Numerous studies are underway, testing new therapies, interventions, and diagnostic tools aimed at preventing, detecting, treating, and managing Alzheimer’s disease.
Alternative Medicine and Alzheimer’s
While various herbal remedies, vitamins, and supplements are promoted for cognitive health, scientific evidence supporting their effectiveness in preventing or treating Alzheimer’s is limited.
Some alternative treatments studied include:
- Vitamin E: While it doesn’t prevent Alzheimer’s, high doses (2,000 IU daily) may modestly slow symptom progression in mild to moderate Alzheimer’s, although research results are mixed and safety at high doses needs further study. It’s crucial to consult healthcare providers due to potential interactions with other medications.
- Omega-3 Fatty Acids: May reduce dementia risk but have not shown benefit in treating Alzheimer’s symptoms.
- Curcumin: Despite anti-inflammatory and antioxidant properties, clinical trials have not demonstrated benefits for Alzheimer’s treatment.
- Ginkgo Biloba: Large studies have found no effect in preventing or delaying Alzheimer’s.
- Melatonin: Studied for sleep management in dementia, but some research suggests it might worsen mood in some individuals, requiring further investigation.
It’s essential to discuss any supplements or alternative treatments with healthcare providers due to potential interactions with prescribed medications.
Lifestyle and Home Remedies for Alzheimer’s
Healthy lifestyle choices are vital for overall well-being and can support brain health in individuals with Alzheimer’s.
Exercise
Regular physical activity is crucial. Daily walks or other exercises can improve mood, maintain joint and muscle health, support heart health, promote better sleep, and prevent constipation. Exercise is also beneficial for caregivers. For those with mobility issues, stationary biking, chair exercises, or stretching can be alternatives. Community centers and online resources offer exercise programs for older adults.
Nutrition
Nutritional support is critical, as individuals with Alzheimer’s may forget to eat, lose interest in food, or neglect healthy eating. Dehydration and constipation are common concerns.
Recommendations include:
- Healthy, Easy-to-Eat Foods: Offer favorite, nutritious foods that are easy to consume.
- Hydration: Encourage regular intake of water and healthy beverages, avoiding caffeinated drinks that can increase restlessness and sleep disruption.
- Nutrient-Rich Shakes and Smoothies: Provide high-calorie, healthy shakes or smoothies, especially when eating becomes challenging.
Social Engagement and Activities
Social activities and engagement are important for maintaining skills, abilities, and overall well-being. Meaningful and enjoyable activities can include listening to music, reading, gardening, crafts, social events at senior centers, and activities with children.
Coping and Support for Alzheimer’s
Individuals with Alzheimer’s and their caregivers face a range of emotional challenges, including confusion, frustration, anger, grief, and depression.
Providing emotional support, reassurance, and maintaining dignity and self-respect are essential. A calm, stable environment can minimize behavioral issues, as new situations, noise, and complex tasks can trigger anxiety.
Caring for the Caregiver
Caregiving for someone with Alzheimer’s is physically and emotionally demanding, leading to stress, guilt, isolation, and health issues for the caregiver. Self-care is paramount.
Caregivers should:
- Educate Themselves: Learn as much as possible about Alzheimer’s disease.
- Seek Information and Support: Ask healthcare professionals and support organizations for guidance.
- Accept Help: Enlist help from friends and family.
- Take Regular Breaks: Schedule daily respite time.
- Maintain Social Connections: Spend time with friends.
- Prioritize Health: Attend to their own health needs, including medical appointments, healthy eating, and exercise.
- Join Support Groups: Connect with caregiver support groups.
- Utilize Adult Day Care: If feasible, use adult day care services.
Counseling and support services are invaluable for both individuals with Alzheimer’s and their families. Local Alzheimer’s Association affiliates can provide resources, support groups, and referrals.
Preparing for a Medical Appointment
Memory loss and cognitive decline require a team-based medical approach. Bringing a family member or friend to medical appointments is highly beneficial for support and information sharing.
For individuals with memory concerns, preparation for appointments includes:
- Medical History: Compile past and current diagnoses and family medical history.
- Medical Team Information: Provide names and contact details of current healthcare providers.
- Medication List: List all medications, including prescriptions, over-the-counter drugs, vitamins, and supplements.
- Symptom Details: Note specific examples of memory and thinking changes.
Healthcare providers will ask questions to understand the nature of cognitive changes, including symptom onset, progression, impact on daily activities, mood changes, and family history. Referral to specialists like neurologists, psychiatrists, or neuropsychologists may be necessary for further evaluation.
This comprehensive guide provides essential information on Alzheimer’s diagnosis and treatment in 2024, emphasizing the importance of early detection, comprehensive care, and ongoing support for individuals and their families.
References
- Jankovic J, et al., eds. Alzheimer disease and other dementias. In: Bradley and Daroff’s Neurology in Clinical Practice. 8th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
- Alzheimer’s disease fact sheet. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet. Accessed Aug. 23, 2024.
- Livingston G, et al. Dementia prevention, intervention and care: 2024 report of the Lancet standing Commission. Lancet. 2024; doi:10.1016/S0140-6736(24)01296-0.
- Chen L, et al. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer’s disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience. 2022; doi:10.3389/fnagi.2022.942629.
- Dementia. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed Aug. 23, 2024.
- Alzheimer’s disease and related dementias. Centers for Disease Control and Prevention. https://www.cdc.gov/aging/aginginfo/alzheimers.htm. Accessed Aug. 23, 2024.
- What is dementia? Symptoms, types, and diagnosis. National Institute on Aging. https://www.nia.nih.gov/health/diagnosing-dementia. Accessed Aug. 23, 2024.
- How biomarkers help diagnose dementia. National Institute on Aging. https://www.nia.nih.gov/health/biomarkers-dementia-detection-and-research. Accessed Aug. 23, 2024.
- Middle-stage caregiving. Alzheimer’s Association. https://www.alz.org/help-support/caregiving/stages-behaviors/middle-stage. Accessed Aug. 23, 2024.
- Kellerman RD, et al. Alzheimer’s disease. In: Conn’s Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
- Ferri FF. Alzheimer disease. In: Ferri’s Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
- Early-stage caregiving. Alzheimer’s Association. https://www.alz.org/help-support/caregiving/stages-behaviors/early-stage. Accessed Aug. 23, 2024.
- Alzheimer’s disease at a glance. National Center for Complementary and Integrative Health. https://nccih.nih.gov/health/alzheimer/ataglance. Accessed Aug. 23, 2024.
- Budson AE, et al. Memory Loss, Alzheimer’s Disease, and Dementia. 3rd ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
- Care in the late stages of Alzheimer’s disease. National Institute on Aging. https://www.nia.nih.gov/health/coping-late-stage-alzheimers-disease. Accessed Aug. 23, 2024.
- Graff-Radford J, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. The Lancet. Neurology. 2021; doi:10.1016/S1474-4422(20)30440-3.
- Naureen Z, et al. Dietary supplements in neurological diseases and brain aging. Journal of Preventve Medicine and Hygience. 2022; doi:10.15167/2421-4248/jpmh2022.63.2S3.2759.
- Is Alzheimer’s genetic? Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics. Accessed Aug. 23, 2024.
- Nimmagadda R. Allscripts EPSi. Mayo Clinic. July 17, 2024.
- Alzheimer’s disease research centers. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-disease-research-centers#minnesota. Accessed Aug. 23, 2024.
- About the Alzheimer’s Consortium. Arizona Alzheimer’s Consortium. https://azalz.org/about/#institutes. Accessed Aug. 23, 2024.
- Lewis JE, et al. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. Journal of Clinical and Translational Research. 2021; doi:10.15167/2421-4248/jpmh2022.63.2S3.2759.
- Home safety. Alzheimer’s Association. https://www.alz.org/help-support/caregiving/safety/home-safety. Accessed Aug. 27, 2024.
- Argyriou S, et al. Beyond memory impairment: The complex phenotypic landscape of Alzheimer’s disease. Trends in Molecular Medicine. 2024; doi:10.1016/j.molmed.2024.04.016.
- Grant WB, et al. Diet’s role in modifying risk of Alzheimer’s disease: History and present understanding. Journal of Alzheimer’s Disease. 2023; doi:10.3233/JAD-230418.
- Wolk DA, et al. Clinical features and diagnosis of Alzheimer disease. https://www.uptodate.com/contents/search. Accessed Aug. 30, 2024.
- Jack Jr. CR, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia. 2024; doi:10.1002/alz.13859.
- 2024 Alzheimer’s disease facts and figures. Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/facts-figures. Accessed Aug. 26, 2024.
- Rosenberg A, et al. Multidomain interventions to prevent cognitive impairment, Alzheimer’s disease and dementia: From FINGER to World-Wide FINGERS. Journal of Prevention of Alzheimer’s Disease. 2020; doi:10.14283/jpad.2019.41.
- Huang L, et al. Mediterranean-dietary approaches to stop hypertension intervention for neurodegenerative delay (MIND) diet and cognitive function and its decline: A prospective study and meta-analysis of cohort studies. The American Journal of Clinical Nutrition. 2023; doi:10.1016/j.ajcnut.2023.04.025.
- Fortea J, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer’s disease. Nature Medicine. 2024; doi:10.1038/s41591-024-02931-w.
- Ashton NJ, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurology. 2024; doi:10.1001/jamaneurol.2023.5319.
- Palmqvist S, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024; doi:10.1001/jama.2024.13855.
- Leqembi (approval letter). Biologic License Application 761269. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761269. Accessed Sept. 5, 2024.
- Liu E, et al. Updates in Alzheimer’s disease: From basic research to diagnosis and therapies. Translational Neurodegeneration. 2024; doi:10.1186/s40035-024-00432-x.
- Shi M, et al. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: A focus on aducanumab and lecanemab. Frontiers in Aging and Neuroscience. 2022; doi:10.3389/fnagi.2022.870517.
- Lecanemab injection. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 6, 2024.
- Kisunla (approval letter). Biologic License Application 761248. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761248. Accessed Sept. 6, 2024.
- Donanemab injection. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 6, 2024.
- Kang C. Donanemab: First approval. Drugs. 2024; doi:10.1007/s40265-024-02087-4.
- Serafin P, et al. Air pollution: A silent key driver of dementia. Biomedicines. 2023; doi:10.3390/biomedicines11051477.
